A multicentre, non- interventional, prospective study Efficacy, safety, tolerability and patient satisfaction of Teriflunomide in patients with relapsing remitting multiple sclerosis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 May 2020 Results assessing clinical outcomes and treatment satisfaction for patients switching from prior disease modifying therapies to teriflunomide in Teri-PRO and TAURUS-MS I studies, presented at the 72nd Annual Meeting of the American Academy of Neurology.
29 Oct 2018 New trial record
12 Oct 2018 Results assessing treatment satisfaction of teriflunomide in clinical trial of TENERE (N=59) and TAURUS-MS I (n=593), presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com